1994年至2000年间在法国分离出的96株炭疽芽孢杆菌的抗生素敏感性
Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000.
作者信息
Cavallo Jean-Didier, Ramisse Francoise, Girardet Monique, Vaissaire Josée, Mock Michelle, Hernandez Eric
机构信息
Laboratoire de Biologie Médicale, Hôpital d'Instruction des Armées Bégin, 94163 Saint-Mandé, France.
出版信息
Antimicrob Agents Chemother. 2002 Jul;46(7):2307-9. doi: 10.1128/AAC.46.7.2307-2309.2002.
Abstract
Ninety-six isolates of Bacillus anthracis recovered in France between 1994 and 2000 were tested for their susceptibilities to 25 different antibiotics. Resistance to penicillin G and amoxicillin was 11.5%. All of the isolates were resistant to cotrimoxazole and susceptible to doxycycline, ciprofloxacin, pefloxacin, levofloxacin, teicoplanin, vancomycin, clindamycin, imipenem, and rifampin.
摘要
对1994年至2000年间在法国分离出的96株炭疽芽孢杆菌进行了25种不同抗生素的药敏试验。对青霉素G和阿莫西林的耐药率为11.5%。所有分离株对复方新诺明耐药，对强力霉素、环丙沙星、培氟沙星、左氧氟沙星、替考拉宁、万古霉素、克林霉素、亚胺培南和利福平敏感。
相似文献
1
Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000.1994年至2000年间在法国分离出的96株炭疽芽孢杆菌的抗生素敏感性
Antimicrob Agents Chemother. 2002 Jul;46(7):2307-9. doi: 10.1128/AAC.46.7.2307-2309.2002.
2
Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.在土耳其分离出的40株炭疽芽孢杆菌的抗菌药敏情况。
Int J Antimicrob Agents. 2003 Jul;22(1):70-2. doi: 10.1016/s0924-8579(03)00097-9.
3
Antimicrobial susceptibility of Bacillus anthracis strains from Hungary.来自匈牙利的炭疽芽孢杆菌菌株的抗菌药敏性。
Acta Vet Hung. 2016 Jun;64(2):141-7. doi: 10.1556/004.2016.015.
4
Antibiotic susceptibility of isolates of Bacillus anthracis, a bacterial pathogen with the potential to be used in biowarfare.炭疽芽孢杆菌（一种有潜力用于生物战的细菌病原体）分离株的抗生素敏感性
Clin Microbiol Infect. 2003 Sep;9(9):984-6. doi: 10.1046/j.1469-0691.2003.00775.x.
5
Selection of Bacillus anthracis isolates resistant to antibiotics.对抗生素具有抗性的炭疽芽孢杆菌分离株的筛选。
J Antimicrob Chemother. 2004 Aug;54(2):424-8. doi: 10.1093/jac/dkh258. Epub 2004 Jun 17.
6
Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods.炭疽芽孢杆菌的抗菌药敏试验：使用美国国家临床实验室标准委员会肉汤微量稀释参考方法和Etest琼脂梯度扩散法所得结果的比较
J Clin Microbiol. 2002 Jun;40(6):1902-7. doi: 10.1128/JCM.40.6.1902-1907.2002.
7
Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits.兔炭疽病单一及联合抗生素治疗的疗效
Antimicrob Agents Chemother. 2015 Dec;59(12):7497-503. doi: 10.1128/AAC.01376-15. Epub 2015 Sep 21.
8
Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model.评估联合药物疗法治疗小鼠模型中抗生素耐药性吸入性炭疽。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00788-17. Print 2017 Sep.
9
MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest.采用Etest法测定来自一系列临床和环境来源的炭疽芽孢杆菌、蜡样芽孢杆菌、苏云金芽孢杆菌和蕈状芽孢杆菌对选定抗生素的最低抑菌浓度。
J Clin Microbiol. 2004 Aug;42(8):3626-34. doi: 10.1128/JCM.42.8.3626-3634.2004.
10
Evaluation of antimicrobial susceptibility of strains isolated during anthrax outbreaks in Italy from 1984 to 2017.对1984年至2017年意大利炭疽疫情期间分离出的菌株进行抗菌药敏评估。
J Vet Sci. 2019 Jan 31;20(1):58-62. doi: 10.4142/jvs.2019.20.1.58.
引用本文的文献
1
An evaluation of antibiotic options for the treatment of biothreat pathogens.用于治疗生物威胁病原体的抗生素选择评估。
Front Antibiot. 2025 Aug 14;4:1611588. doi: 10.3389/frabi.2025.1611588. eCollection 2025.
2
Anthrax: A narrative review.炭疽：一篇叙述性综述。
New Microbes New Infect. 2024 Oct 10;62:101501. doi: 10.1016/j.nmni.2024.101501. eCollection 2024 Dec.
3
Rational corticosteroids administration and antibiotic treatment is key to managing cutaneous anthrax.合理使用皮质类固醇和抗生素治疗是治疗皮肤炭疽的关键。
BMC Infect Dis. 2024 Oct 31;24(1):1225. doi: 10.1186/s12879-024-09922-9.
4
Anthrax in Humans, Animals, and the Environment and the One Health Strategies for Anthrax Control.人类、动物和环境中的炭疽以及炭疽防控的一体化健康策略
Pathogens. 2024 Sep 7;13(9):773. doi: 10.3390/pathogens13090773.
5
Antimicrobial Resistance Profile, Whole-Genome Sequencing and Core Genome Multilocus Sequence Typing of Isolates in Croatia from 2001 to 2022.2001年至2022年克罗地亚分离株的抗菌药物耐药性概况、全基因组测序和核心基因组多位点序列分型
Antibiotics (Basel). 2024 Jul 11;13(7):639. doi: 10.3390/antibiotics13070639.
6
Genetic basis of clarithromycin resistance in .克拉霉素耐药的遗传基础。
Microbiol Spectr. 2024 Jun 4;12(6):e0418023. doi: 10.1128/spectrum.04180-23. Epub 2024 Apr 26.
7
CDC Guidelines for the Prevention and Treatment of Anthrax, 2023.2023 年美国疾病预防控制中心炭疽病预防和治疗指南。
MMWR Recomm Rep. 2023 Nov 17;72(6):1-47. doi: 10.15585/mmwr.rr7206a1.
8
Recombinant full-length protective antigen and its 63 kDa form elicits protective response in formulation with addavax.与 Addavax 联合使用时，重组全长保护性抗原及其 63 kDa 形式可引发保护性应答。
Front Immunol. 2023 Jan 12;13:1075662. doi: 10.3389/fimmu.2022.1075662. eCollection 2022.
9
Risk Factors for Severe Cutaneous Anthrax in a Retrospective Case Series and Use of a Clinical Algorithm to Identify Likely Meningitis and Evaluate Treatment Outcomes, Kyrgyz Republic, 2005-2012.2005-2012 年吉尔吉斯斯坦回顾性病例系列研究的严重皮肤炭疽危险因素和临床算法的应用，以确定可能的脑膜炎并评估治疗结果。
Clin Infect Dis. 2022 Oct 17;75(Suppl 3):S478-S486. doi: 10.1093/cid/ciac537.
10
Systematic Review of In Vitro Antimicrobial Susceptibility Testing for Bacillus anthracis, 1947-2019.1947-2019 年炭疽杆菌体外药敏试验的系统评价
Clin Infect Dis. 2022 Oct 17;75(Suppl 3):S373-S378. doi: 10.1093/cid/ciac520.
本文引用的文献
1
In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne.炭疽芽孢杆菌斯特恩株对氧氟沙星和强力霉素的体外耐药性发展
Antimicrob Agents Chemother. 2000 Jun;44(6):1766. doi: 10.1128/AAC.44.6.1766-1766.2000.
2
Inhalational anthrax: epidemiology, diagnosis, and management.吸入性炭疽：流行病学、诊断与管理
Chest. 1999 Nov;116(5):1369-76. doi: 10.1378/chest.116.5.1369.
3
The medical threat of biological weapons.生物武器的医学威胁。
Crit Rev Microbiol. 1998;24(3):157-68. doi: 10.1080/10408419891294280.
4
Bacillus thuringiensis subsp. konkukian (serotype H34) superinfection: case report and experimental evidence of pathogenicity in immunosuppressed mice.苏云金芽孢杆菌韩国亚种（血清型H34）重复感染：免疫抑制小鼠致病性的病例报告及实验证据
J Clin Microbiol. 1998 Jul;36(7):2138-9. doi: 10.1128/JCM.36.7.2138-2139.1998.
5
Identification and characterization of Bacillus anthracis by multiplex PCR analysis of sequences on plasmids pXO1 and pXO2 and chromosomal DNA.通过对质粒pXO1和pXO2以及染色体DNA上的序列进行多重PCR分析来鉴定和表征炭疽芽孢杆菌。
FEMS Microbiol Lett. 1996 Nov 15;145(1):9-16. doi: 10.1111/j.1574-6968.1996.tb08548.x.
6
A macrolide-lincosamide-streptogramin B resistance determinant from Bacillus anthracis 590: cloning and expression of ermJ.来自炭疽芽孢杆菌590的大环内酯-林可酰胺-链阳菌素B抗性决定簇：ermJ的克隆与表达
J Gen Microbiol. 1993 Mar;139(3):601-7. doi: 10.1099/00221287-139-3-601.
7
Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979.1979年斯维尔德洛夫斯克炭疽疫情中42例吸入性炭疽的病理学研究
Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2291-4. doi: 10.1073/pnas.90.6.2291.
8
Bacillus cereus and related species.蜡样芽孢杆菌及相关菌种。
Clin Microbiol Rev. 1993 Oct;6(4):324-38. doi: 10.1128/CMR.6.4.324.
9
[Characterization of a Rif-R population of Bacillus anthracis].[炭疽芽孢杆菌耐利福平群体的特性分析]
Antibiot Khimioter. 1993 Aug-Sep;38(8-9):34-8.
10
Outbreak of oral-oropharyngeal anthrax: an unusual manifestation of human infection with Bacillus anthracis.
Am J Trop Med Hyg. 1984 Jan;33(1):144-50. doi: 10.4269/ajtmh.1984.33.144.
Zotero 插件